Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Induced Pluripotent Stem Cell (iPSC) Market Size, Trends & Forecasts 2026-2034 by Application, Technology, Cell Type and Region

globenewswire.com
TMO Thermo Fisher Scientific is mentioned as a major life sciences supplier contributing to the commercialization of iPSC-derived products, manufacturing technologies, and research workflows. The article does not provide specific sentiment towards Thermo Fisher Scientific's performance or prospects. MRK Merck is listed as a major life sciences supplier contributing to the commercialization of iPSC-derived products, manufacturing technologies, and research workflows. The article does not offer specific sentiment regarding Merck's involvement or performance in this market. BDX BD Biosciences (Becton Dickinson) is mentioned as a major life sciences supplier contributing to the commercialization of iPSC-derived products, manufacturing technologies, and research workflows. No specific sentiment is provided for Becton Dickinson.

Induced Pluripotent Stem Cell (iPSC) Market Size, Trends & Forecasts 2026-2034 by Application, Technology, Cell Type and Region Dublin, Aug. 10, 2026 (GLOBE NEWSWIRE) -- The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2026" has been added to ResearchAndMarkets.com's offering.

Global Induced Pluripotent Stem Cell Market Advances Through Clinical Innovation, Investment and Commercial Expansion

The global induced pluripotent stem cell (iPSC) market continues to expand as advances in regenerative medicine, cell and gene therapy, drug discovery and disease modeling accelerate commercial adoption. Since iPSC technology emerged in 2006, researchers and biotechnology companies have identified new disease mechanisms, developed more relevant drug-screening platforms and advanced iPSC-derived cell therapies into human clinical trials.

Commercial applications for induced pluripotent stem cells now span therapeutic development, research services and industrial biotechnology. Key areas include:

iPSC Market Dynamics

The induced pluripotent stem cell sector has progressed rapidly from laboratory research to clinical evaluation. The first transplantation of an iPSC-derived cell product took place in Japan in 2013, only seven years after the technology was introduced. Led by Dr. Masayo Takahashi at the RIKEN Center in Kobe, the study evaluated iPSC-derived retinal tissue in patients with macular degeneration.

In 2016, Cynata Therapeutics received approval to initiate a clinical trial of CYP-001, an allogeneic iPSC-derived mesenchymal stem cell product for steroid-resistant acute graft-versus-host disease. The program subsequently reported positive safety and efficacy results and met its clinical endpoints, supporting broader interest in scalable, allogeneic iPSC therapies.

At least 228 clinical trials now involve iPSC technology, including 66 trials evaluating iPSC-derived cells as therapeutic products. Most therapeutic studies remain in Phase I or Phase II and address conditions such as Parkinson's disease, retinal disorders, heart failure, immune diseases and Type 1 diabetes. Investigational products include dopaminergic progenitors, retinal pigment epithelial cells, insulin-secreting beta cells, mesenchymal stem cells and iPSC-derived natural killer cells for cancer immunotherapy.

Investment and consolidation are also shaping the iPSC market. Recent transactions include Axol Bioscience's acquisitions of Newcells Biotech and Phenocell, as well as Century Therapeutics' $35 million acquisition of Clade Therapeutics. Strategic partnerships and licensing agreements increasingly focus on good manufacturing practice-compliant production, automation, quality control and off-the-shelf allogeneic cell therapies.

Venture capital investment in the sector totaled approximately $1.04 billion between 2023 and April 2026, compared with a peak of $2.15 billion in 2021. Funding has increasingly favored companies with proprietary manufacturing platforms, differentiated intellectual property and clear pathways from research products to clinical-stage therapeutics.

Competitive Landscape

FUJIFILM Cellular Dynamics International remains a major participant in the global iPSC industry. Cellular Dynamics International, founded in 2004 by Dr. James Thomson, became an early developer of human iPSC lines. FUJIFILM acquired the company for $307 million in 2015, creating a large-scale supplier of human iPSC-derived cells for research, drug development and regenerative medicine.

ReproCELL was among the first companies to commercialize iPSC products, including its ReproCardio cardiomyocyte portfolio. European market participants include Evotec, which has developed an industrialized iPSC drug-discovery platform, and Ncardia, which specializes in cardiac and neural cell applications.

Major life sciences suppliers, including Lonza, BD Biosciences, Thermo Fisher Scientific, Merck and Takara Bio, also contribute to the commercialization of iPSC-derived products, manufacturing technologies and research workflows. More than 90 companies are active across the broader induced pluripotent stem cell market, serving research, pharmaceutical and therapeutic customers.

Global iPSC Market Report Scope

The global iPSC market report examines the companies, technologies, partnerships and clinical programs influencing industry growth. Coverage includes iPSC research, cell manufacturing, patents, scientific publications, clinical trials, fundraising, initial public offerings, mergers and acquisitions, licensing transactions and co-development agreements.

The report also analyzes the growing use of iPSCs in drug discovery, toxicology, disease modeling and regenerative medicine. Market estimates and forecasts through 2034 are segmented by application, technology, cell type and geography, including North America, Europe, Asia-Pacific and the rest of the world.

Continued progress in scalable manufacturing, cell differentiation, genome editing and clinical development is expected to strengthen the commercial outlook for induced pluripotent stem cells. As therapeutic programs mature and research applications broaden, iPSC technology is positioned to play an increasingly important role in precision medicine, pharmaceutical development and next-generation cell therapies.

Key Topics Covered

1. Report Overview

2. Introduction

3. Current Status of iPSC Industry

4. iPSC Manufacturing

5. Research Publications on Induced Pluripotent Stem Cells

6. iPSC Patent Landscape

7. Clinical Trial Landscape: Induced Pluripotent Stem Cells

8. M&A, Collaborations and Funding Activities in iPSC Sector

9. Generation of Induced Pluripotent Stem Cells (iPSCs)

10. Human iPSC Banking

11. Biomedical Applications of iPSCs

12. Market Analysis

13. Company Profiles

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/vx71rh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.